- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Emerging PSMA Radioligand Therapy Shows Benefits for Metastatic Castration-Resistant Prostate Cancer
The PSMA-targeted modality 177Lu-PNT2002 improved radiographic progression-free survival by 29 percent in patients with mCRPC in comparison to ARPI therapy, according to new phase 3 trial data presented at the ESMO Congress in Spain.
Emerging research presented at the European Society of Medical Oncology (ESMO) Congress suggests that the prostate-specific membrane antigen (PSMA)-targeted radioligand therapy 177Lu-PNT2002 offers significant advantages over androgen-receptor pathway inhibitor (ARPI) treatment of PSMA-positive patients with metastatic castration-resistant prostate cancer (mCRPC).
In the SPLASH phase 3 randomized trial, researchers compared the administration of 177Lu-PNT2002 (6.8 GBq every eight weeks for up to four treatment cycles) to ARPI therapies (abiraterone and enzalutamide) in 412 patients with mCRPC.1
The researchers found that 177Lu-PNT2002 (Lantheus) bolstered radiographic progression-free survival (rPFS) by 29 percent and led to a 3.5 month increase in median rPFS (9.5 months vs. 6.5 months) in contrast to ARPI therapy.1,2
The use of the radioligand therapy 177Lu-PNT2002 was also associated with a longer median duration of response (9.4 months vs. 7.3 months), more than double the PSA50 response rate (35.7 percent vs. 14.6 percent) and longer median biochemical progression-free survival (seven months vs. 3.9 months) in comparison to ARPI modalities, according to the study authors.2
In recent phase 3 trial research presented at the ESMO Congress 2024, researchers found that the PSMA-targeted radioligand 177Lu-PNT2002 offered significantly improved median radiographic progression-free survival (rPFS), biochemical progression-free survival (bPFS) and treatment duration response in comparison to androgen-receptor pathway inhibitor (ARPI) treatment of PSMA-positive patients with metastatic castration-resistant prostate cancer (mCRPC).
“These initial data underscore the importance of PSMA-targeted RLTs, including 177Lu-PNT2002, as potential treatment options for patients who have limited choices after progressing on ARPI therapy,”noted Oliver Sartor, M.D., the director of radiopharmaceutical trials and a professor of medical oncology at the Mayo Clinic in Rochester, Minnesota.
(Editor's note: For related content on imaging for prostate cancer, click here.)
The researchers also pointed out that 177Lu-PNT2002 had lower safety risks than ARPI therapy. Specifically, patients in the 177Lu-PNT2002 cohort had a lower rate of treatment-related serious adverse events (AEs) (2.2 percent vs. 3.8 percent). The study authors said those who had 177Lu-PNT2002 had a greater than threefold lower rate of halted or reduced treatment due to treatment-emergent adverse events (TEAEs) in comparison to patients who had ARPI therapy (3 percent vs. 11.5 percent).1,2
References
1. Lantheus. Lantheus presents results from the primary analysis of phase 3 pivotal SPLASH trial in PSMA-positive metastatic castration-resistant prostate cancer during ESMO Congress 2024. Available at: https://investor.lantheus.com/news-releases/news-release-details/lantheus-presents-results-primary-analysis-phase-3-pivotal . Published September 15, 2024. Accessed September 16, 2024.
2. Sartor O, Jiang DM, Smoragiewicz M, et al. Efficacy of 177LU-PNT2002 in PSMA-positive mCRPC following progression on an androgen-receptor pathway inhibitor (ARPI) (SPLASH). Presented at the European Society for Medical Oncology (ESMO) Congress September 13-17, 2024, Barcelona, Spain. Available at: https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session/list? . Accessed September 16, 2024.
Can MRI-Based Deep Learning Improve Risk Stratification in PI-RADS 3 Cases?
January 30th 2025In external validation testing, a deep learning model demonstrated an average AUC of 87.6 percent for detecting clinically significant prostate cancer (csPCA) on prostate MRI for patients with PI-RADS 3 assessments.
Emerging PET Agent Garners Second FDA Fast Track Designation for Prostate Cancer Imaging
January 24th 2025In addition to an August FDA fast track designation for PSMA PET imaging in patients with suspected metastasis, the radiopharmaceutical 64Cu-SAR-bisPSMA has earned another fast track designation for imaging of biochemical recurrence.
Study Examines Prognostic Value of Baseline PSMA PET/CT Factors in Patients with mCRPC
January 24th 2025Doubling of total tumor volume on PSMA PET/CT is 41 percent more likely to reduce overall survival in patients with metastatic castration-resistant prostate cancer (mCRPC), according to new research.
Can Deep Learning Radiomics with bpMRI Bolster Accuracy for Prostate Cancer Prognosis?
January 22nd 2025An emerging deep learning radiomics model based on biparametric MRI (bpMRI) offered a 14 to 17 percent higher AUC range than PI-RADS scoring for predicting the aggressiveness of prostate cancer, according to new research findings.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
